Nonetheless, the substantial therapeutic potential of directing focus towards the NLRP3 inflammasome and its associated pyroptotic pathway in the management of NAFLD warrants considerable attention. This evidence concerns the gene NLRP3 and metabolic dysfunction-associated steatotic liver disease.